Neuberger Berman Group
MRNA icon

Neuberger Berman Group’s Moderna MRNA Stock Holding History

Neuberger Berman Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.06M Buy
99,545
+5,625
+6% +$262K ﹤0.01% 980
2025
Q4 		$2.77M Buy
93,920
+14,440
+18% +$392K ﹤0.01% 1093
2025
Q3 		$2.05M Buy
79,480
+17,843
+29% +$498K ﹤0.01% 1157
2025
Q2 		$1.7M Sell
61,637
-29
-0% -$764 ﹤0.01% 1192
2025
Q1 		$1.75M Buy
61,666
+17,309
+39% +$614K ﹤0.01% 1166
2024
Q4 		$1.84M Sell
44,357
-43,144
-49% -$2.06M ﹤0.01% 1156
2024
Q3 		$5.85M Sell
87,501
-167,320
-66% -$15.4M ﹤0.01% 913
2024
Q2 		$30.3M Buy
254,821
+66,267
+35% +$8.39M 0.02% 547
2024
Q1 		$20.1M Buy
188,554
+61,911
+49% +$6.24M 0.02% 641
2023
Q4 		$12.6M Buy
126,643
+8,641
+7% +$727K 0.01% 732
2023
Q3 		$12.2M Buy
118,002
+36,293
+44% +$4.05M 0.01% 712
2023
Q2 		$9.93M Buy
81,709
+14,216
+21% +$1.9M 0.01% 749
2023
Q1 		$10.4M Buy
67,493
+4,565
+7% +$753K 0.01% 743
2022
Q4 		$11.3M Buy
62,928
+4,289
+7% +$701K 0.01% 727
2022
Q3 		$6.94M Sell
58,639
-1,862
-3% -$283K 0.01% 812
2022
Q2 		$8.65M Buy
60,501
+26,761
+79% +$3.83M 0.01% 778
2022
Q1 		$5.82M Buy
33,740
+1,649
+5% +$278K ﹤0.01% 926
2021
Q4 		$7.71M Sell
32,091
-26,983
-46% -$7.89M 0.01% 881
2021
Q3 		$22M Sell
59,074
-5,407
-8% -$1.99M 0.02% 655
2021
Q2 		$15M Buy
64,481
+29,981
+87% +$5.36M 0.01% 758
2021
Q1 		$4.5M Buy
34,500
+21,845
+173% +$3.17M ﹤0.01% 972
2020
Q4 		$1.31M Sell
12,655
-158,500
-93% -$16M ﹤0.01% 1191
2020
Q3 		$12.1M Buy
171,155
+46,679
+38% +$3.25M 0.01% 694
2020
Q2 		$7.99M Buy
124,476
+3,988
+3% +$218K 0.01% 763
2020
Q1 		$3.61M Sell
120,488
-519,718
-81% -$12M 0.01% 838
2019
Q4 		$12.5M Buy
640,206
+200
+0% +$3.55K 0.01% 698
2019
Q3 		$10.2M Sell
640,006
-748,108
-54% -$11.1M 0.01% 713
2019
Q2 		$20.3M Buy
1,388,114
+683,159
+97% +$14.7M 0.02% 597
2019
Q1 		$14.3M Sell
704,955
-242,070
-26% -$4.49M 0.02% 667
2018
Q4 		$14.5M Buy
+947,025
New +$15.6M 0.02% 650

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Neuberger Berman Group's MRNA Position: Q1 2026 in Review

Neuberger Berman Group increased its Moderna (MRNA) stake by 6% in Q1 2026, buying an estimated $262K and bringing the position to 99,545 shares worth $5.06M. The position accounts for ﹤0.01% of the portfolio, ranked #980.

Neuberger Berman Group first reported a position in MRNA in Q4 2018 and has held it in 30 quarters since. The position peaked at $30.3M in Q2 2024. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Neuberger Berman Group held 99,545 shares of Moderna worth $5.06M as of Q1 2026.
  • Neuberger Berman Group bought 5,625 Moderna shares in Q1 2026, an estimated $262K.
  • Moderna made up ﹤0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #980 holding.
  • Neuberger Berman Group first reported a position in Moderna in Q4 2018 and has held it in 30 quarters since.
  • Neuberger Berman Group's Moderna position peaked at $30.3M in Q2 2024.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.